Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)

Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)

10.1093/ofid/ofab387

Saved in:
Bibliographic Details
Main Authors: Stewart, AG, Paterson, DL, Young, B, Lye, DC, Davis, JS, Schneider, K, Yilmaz, M, Dinleyici, R, Runnegar, N, Henderson, A, Archuleta, S, Kalimuddin, S, Forde, BM, Chatfield, MD, Bauer, MJ, Lipman, J, Harris-Brown, T, Harris, PNA
Other Authors: MEDICINE
Format: Article
Published: Oxford University Press (OUP) 2021
Subjects:
Enterobacterales
ampC β-lactamase
carbapenem
clinical trial
piperacillin-tazobactam
Online Access:https://scholarbank.nus.edu.sg/handle/10635/206194
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Internet

https://scholarbank.nus.edu.sg/handle/10635/206194

Similar Items